Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash & Equivalents (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Cash & Equivalents readings, the most recent being $8.4 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 39.31% to $8.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $8.4 million, a 39.31% decrease, with the full-year FY2025 number at $8.5 million, down 66.04% from a year prior.
  • Cash & Equivalents hit $8.4 million in Q1 2026 for Atara Biotherapeutics, down from $8.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $101.7 million in Q1 2022 to a low of $5.7 million in Q3 2025.
  • Median Cash & Equivalents over the past 5 years was $35.1 million (2024), compared with a mean of $41.6 million.
  • Biggest five-year swings in Cash & Equivalents: fell 0.5% in 2023 and later plummeted 87.64% in 2025.
  • Atara Biotherapeutics' Cash & Equivalents stood at $92.9 million in 2022, then crashed by 72.2% to $25.8 million in 2023, then fell by 3.14% to $25.0 million in 2024, then crashed by 66.04% to $8.5 million in 2025, then fell by 1.18% to $8.4 million in 2026.
  • The last three reported values for Cash & Equivalents were $8.4 million (Q1 2026), $8.5 million (Q4 2025), and $5.7 million (Q3 2025) per Business Quant data.